Health Reform Endgame: Medicare Advantage For All?
Executive Summary
The political dynamics of the health care debate are changing again, and now Democrats are likely to return to universal coverage as a high-profile campaign theme. Is there a US “single-payer” model that might actually work out for biopharma innovators?
You may also be interested in...
PBM Integration: Economists Outline Benefits Of Mergers In Senate Hearing
Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.
Obamacare Is Dead – Long Live The ACA
Making sense of the 'Repeal And Replace' effort in 2017, and thinking through the implications for 2018 and beyond.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.